A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective
References (44)
The natural history of multiple sclerosis
Neurol Clin
(1995)- Leitlinien der DGN 2008. Diagnostik and Therapie der Multiplen...
Multiple sclerosis and other demyelinating diseases
- et al.
Multiple sclerosis
N Engl J Med
(2000) - et al.
The natural history of multiple sclerosis: A geographically-based study. 2. Predictive value of the early clinical course
Brain
(1989) - et al.
Neuroimaging evaluation in multiple sclerosis
Am Fam Physician
(1993) The use and misuse of statistics for epidemiological studies of multiple sclerosis
Ann Neurol
(1994)Therapeutic advances: Beta-interferon for multiple sclerosis
J Clin Pharm Ther
(1996)- et al.
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials
Arch Neurol
(1989)
Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis
Arch Neurol
(1992)
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353:678]
Lancet
(1998)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
Neurology
(1993)
Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of sec ondary progressive multiple sclerosis
Lancet
(1998)
Economic status of families living with multiple sclerosis
Int J Rehabil Res
(1992)
Costs and quality of life of multiple sclerosis in Germany
Eur J Health Econ
(2006)
The National Multiple Sclerosis Survey. Background and economic impact
Ann N Y Acad Sci
(1984)
Meta-analysis of the placebo-treated groups in clinical trials of progressive MS
Neurology
(1996)
The role of disease and demographic factors in the employment of patients with multiple sclerosis
Arch Neurol
(1982)
Prognostic criteria in multiple sclerosis
Ann N Y Acad Sci
(1965)
Multivariate analyses of factors associated with unemployment in people with multiple sclerosis
J Neurol Neurosurg Psychiatry
(1990)
Cited by (20)
Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review
2021, Expert Review of Pharmacoeconomics and Outcomes ResearchDisease modifying therapies in multiple sclerosis: Cost-effectiveness systematic review
2020, Farmacia HospitalariaCost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
2015, PharmacoEconomics
Copyright © 2010 Excerpta Medica Inc. All rights reserved.